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Effects of Endothelial
Nitric Oxide Synthase Gene
Polymorphisms on Oxidative
Stress, Inflammatory Status,
and Coronary Atherosclerosis: An
Example of a Transient Phenotype
In their recent study, Rossi et al. (1) showed that the T786C
polymorphism on the promoter region of the endothelial nitric
oxide synthase (eNOS) gene modifies redox-sensitive inflamma-
tory pathways, and may be a predictor for clinical outcome in
high-risk patients with coronary atherosclerosis. Although this
polymorphism was found to be in linkage disequilibrium with the
functional polymorphism G894T (D=  0.3), the latter had no
predictive value in this cohort, despite the results of a large
meta-analysis suggesting the opposite (2). However, the observa-
tion that the 894T/786T haplotype leads to a worse cardiovascular
death-free survival supports the hypothesis of a more complex
association between these polymorphisms and eNOS function.
We have recently shown (3) that the presence of the 894T allele
is associated with higher levels of oxidized low-density lipoprotein
and proinflammatory cytokines only under conditions of “biolog-
ical stress,” such as during the acute phase of myocardial infarction,
an effect not observed in the same subjects 1 year after the event,
or in healthy individuals. Moreover, the 894T allele seems to be
associated with impaired endothelial function in high-risk patients
(4) and in healthy smokers (5), but not in healthy, low-risk
individuals (5).
In the present study, Rossi et al. (1) actually introduce the
hypothesis that the previously observed transient effect of the 894T
allele on oxidative stress, inflammatory process, and endothelial
function (3–5) could actually be due to its linkage disequilibrium
with the 786T allele (which has been suggested to modify eNOS
expression). However, this could be due to the complex interaction
of both polymorphisms constituting the 894T/786T haplotype.
The combination of low eNOS expression (induced by the 786T
allele) and increased susceptibility of eNOS to proteolytic cleavage
(induced by the 894T allele) (6) could lead to a combined effect on
the associated phenotype of nitric oxide bioavailability, and the
subsequent alterations of oxidative stress and inflammatory status.
Therefore, further molecular studies are required to explore the
transient behavior of eNOS genotypes/haplotypes, leading to a
different phenotype, depending on the underlying disease state.
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Reply
To explain our (1) intriguing results on the effects of the T-786C (in
the promoter) and the G894T (in exon 7) single nucleotide polymor-
phisms (SNP) of the endothelial nitric oxide (NO) synthase (eNOS)
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gene on cardiovascular mortality, Tanus-Santos et al. recalled that the
former SNP alters the gene responsiveness to statins: statins would
up-regulate eNOS expression (2) more potently in -786C homozy-
gous (3) and therefore, these subjects would generate more NO while
on statins than subjects with the other genotypes. Accordingly,
atorvastatin increased NO availability and reduced inflammatory
marker concentrations in CC, but not in TT healthy men (4).
However, we found no significant interaction between statin treat-
ment and the T-786C SNP affecting cardiovascular mortality (1).
Moreover, only a minority of our patients were on statins (5);
therefore, this mechanistic explanation is unlikely.
As with Tanus-Santos et al., we also found that the T-786C SNP
did not affect nitrite/nitrate levels; however, functional data (6)
indicate that the T-786C SNP affects NO bioactivity by altering the
gene responsiveness to shear stress (7). Thus, the “Janus” nature of
eNOS might reveal itself under conditions of oxidant stress, leading to
decreased plaque stability and cardiovascular events (1).
Antoniades et al. raised another appealing hypothesis: an
interaction of the 786T with the 894T allele constituting the
894T/786T haplotype might lower eNOS expression and increase
susceptibility of eNOS to proteolytic cleavage, resulting into
transiently increased oxidant stress and inflammatory status during
acute conditions (8). However, the G894T SNP lies within a loop
on the external surface of eNOS and does not make contact with
either the active site of the enzyme, or the dymerization interface,
suggesting that, if functional, this SNP could act by a mechanism
independent of eNOS catalysis. Moreover, the increased suscep-
tibility to cleavage of the Asp298-encoded eNOS enzyme has been
shown to be artifactual (reviewed by Casas et al.) (9). Therefore,
whether the 894T allele bears functional consequences remains
controversial. Nonetheless, the linkage disequilibrium of the
T-786C and G894T SNP (1) can explain the association of the
latter SNP with coronary heart disease (CHD), as we pointed out.
Antoniades et al. stated that an increased risk of CHD (odds ratio
[OR]  1.31) for the 894T allele carriers was reported; however, the
excess risk deriving from meta-analysis of cross-sectional association
studies, which are prone to stratification biases, should be viewed
cautiously. In fact, a much larger meta-analysis led to a markedly
reduced estimate of risk (OR  1.17) (9).
Consistent with prospective study results in high-risk patients
(1,10), we found no evidence for a prognostic effect of the 894T
allele. Thus, even if the 894T homozygosity would imply a blunted
NO production and/or higher levels of oxidized low-density
lipoprotein and proinflammatory cytokines during acute coronary
events, overall prospective cohort studies show no prognostic effect
in high-risk patients.
Finally, although underlying the fact that intriguing results such
as ours are crucial for generating novel hypotheses, we agree that
the elucidation of the complex interplay between the eNOS gene
haplotypes and environmental factors deserves further research.
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Noncardiac Findings in
Computed Tomography
Coronary Angiography
The report by Onuma et al. (1) on noncardiac findings in
multidetector computed tomography (MDCT) and the accompa-
nying editorial comment by Rumberger (2) raise interesting issues.
Onuma et al. (1) found that approximately 23% of 503 patients
undergoing CT coronary angiography demonstrated significant
noncardiac pathology requiring follow-up. This included 2 lung
and 2 breast malignancies. Similarly, Baum et al. (3) have recently
reported a high prevalence of extracardiac disease, including
malignancies, among over a thousand patients undergoing
MDCT.
Rumberger (2) suggests medico-legal and moral imperatives to
seek noncardiac pathology. The patient’s entire chest and upper
abdomen have been irradiated, after all, and the imaging data are
there awaiting reconstruction. Although this approach seems very
reasonable, I believe we need to keep an open mind, recognizing
the absence of hard evidence that the pursuit of extracardiac
pathology leads to overall improved patient outcomes. Much of the
noncardiac pathology, such as liver and renal cysts, is relatively
unimportant and probably unrelated to the symptom of chest pain.
With regard to more serious pathology, several questions arise:
When found, are the newly discovered malignancies curable or
amenable to treatment that prolongs life or improves quality of
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